Imugene Ltd (IUGNF) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The phase I MAST study tests Imugene Ltd’s oncolytic virus VAXINIA (CF33-hNIS) in adults with advanced or metastatic solid tumors, aiming to assess safety, dosing, and early signs of benefit in a hard‑to‑treat group. The official title confirms a focus on dose escalation and tolerability for both solo and combo use, positioning VAXINIA as a potential new tool in solid cancer care.
The main treatment is CF33-hNIS, also called VAXINIA, an engineered virus designed to infect and kill cancer cells while sparing healthy tissue. It is given alone or together with Merck’s immunotherapy pembrolizumab (KEYTRUDA) or a chemo mix called modified FOLFOX, to see if combinations boost anti‑tumor activity.
The trial is interventional and non‑randomized, meaning all patients receive active treatment rather than placebo, with groups enrolled in sequence to test rising dose levels. It is open label, so doctors and patients know what they are getting, and the core aim is treatment focused: map out safe dosing and how patients tolerate VAXINIA by different routes.
The study was first submitted in March 2022, marking the formal start of clinical development for this program in advanced solid tumors. The most recent update was filed on March 4, 2026, and the status has shifted to terminated, signaling that enrollment or dosing has stopped and that the sponsor is now likely reviewing emerging safety and activity data.
For investors, the termination of this early study can weigh on near‑term sentiment toward Imugene’s IUGNF shares, as it raises questions about the future of VAXINIA in solid tumors. At the same time, the broader field of oncolytic viruses and immuno‑oncology remains active, with large players like Merck and other biotech peers pushing competing approaches that may attract capital away from higher‑risk small caps.
The latest ClinicalTrials.gov record confirms the MAST study has been terminated and updated, and investors can find further details and status notes directly on the ClinicalTrials portal.
To learn more about IUGNF’s potential, visit the Imugene Ltd drug pipeline page.